{"preliminary_commentary":{"by_channel":{"x_thread":20,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06767514\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["ivonescimab"]],"indication":"first-line metastatic NSCLC with high PD-L1 expression","name":"HARMONi-7","nct_id":"NCT06767514","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=harmoni-7-nct06767514. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"HARMONi-7","arms":[{"description":"Subject will receive ivonescimab as an IV injection","label":"Arm A - Ivonescimab","type":"EXPERIMENTAL"},{"description":"Subject will receive pembrolizumab as an IV injection","label":"Arm B - Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-06","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":780,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ivonescimab Injection","otherNames":[],"type":"BIOLOGICAL"},{"name":"Pembrolizumab Injection","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-09-18","lead_sponsor":"Summit Therapeutics","official_title":"A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 36 months"},{"measure":"Progression free survival (PFS)","timeFrame":"Up to approximately 36 months"}],"references":[],"start_date":{"date":"2025-02-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","url":"https://clinicaltrials.gov/study/NCT06767514"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/harmoni-7-nct06767514"}